Intrathecal MSC-NP injection

BIOLOGICAL2 trials

Sponsors

Tisch Multiple Sclerosis Research Center of New York

Conditions

Multiple Sclerosis

Phase 2

Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis

CompletedNCT03355365

Tisch Multiple Sclerosis Research Center of New YorkMultiple Sclerosis

Start: 2018-09-21End: 2023-04-17Updated: 2025-06-11

Unknown Phase

Expanded Access to Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis

Tisch Multiple Sclerosis Research Center of New YorkMultiple Sclerosis

Updated: 2025-08-17

Related Papers

Efficacy of intrathecal mesenchymal stem cell-neural progenitor therapy in progressive MS: results from a phase II, randomized, placebo-controlled clinical trial.

2024-05-2311 citations

Efficacy and safety of Lenzumestrocel (Neuronata-R® inj.) in patients with amyotrophic lateral sclerosis (ALSUMMIT study): study protocol for a multicentre, randomized, double-blind, parallel-group, sham procedure-controlled, phase III trial

Trials2022-05-1815 citations